cvs health glp-1 receptor agonists weight management diabetes treatments MinuteClinic Weight-Loss Program expands access to care GLP-1 Resource Center

A comprehensive meta-analysis of eight GLP-1 RA CVOTs revealed several critical findings: 14% reduction in major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) [3] 13% reduction in cardiovascular death [3] 10% reduction in all-cause mortality [3] 11% reduction in hospitalization for heart failure [3] Post-hoc analyzes from LEADER and SUSTAIN-6 revealed that cardiovascular benefits extended across the spectrum of body mass index categories, indicating efficacy regardless of baseline weight [2]

& Reboucas, N

The review discusses several classes of therapies, including: Mono-agonists: Liraglutide, dulaglutide, and semaglutide

[DOI] [PubMed] [Google Scholar] 70.Rangaswami J., Bhalla V., Blair J.E.A., Chang T.I., Costa S., Krista L.L., Lerma E.V., Mezue K., Molitch M., Mullens W., et al

In an earlier 54-week study, 9 of 23 patients who received liraglutide had resolution of definite non-alcoholic steatohepatitis compared to 2 of 22 patients in the placebo group (NCT01237119)